AttheForefrontofDrugDiscoveryChinaNovartisInstitutes.pdfVIP

At the Forefront of Drug Discovery China Novartis Institutes for BioMedical Research 在创新药物研发的最前沿 诺华（中国）生物医学研究中心 2 3 A LONG-TERM COMMITMENT TO 承诺中国长期发展 CHINA China Novartis Institutes for BioMedical Research (CNIBR) is part of the 诺华 ( 中国) 生物医学研究中心 (CNIBR) 是诺华全球药物研发机构的一部分。2007 年， The first integrated Novartis global RD network. The Novartis Shanghai RD center opened in 新成立的诺华上海研发中心正式投入运营，成为跨国医药健康企业中首家、也是规模 跨国医药健康企业中首 RD center and 2007 as the first integrated RD center and the largest among multinational 最大的综合性研发中心。 家、也是规模最大的综 corporations in China. the largest among 合性研发中心 目前，诺华在上海浦东新区张江高科技园区的研发基地拥有 500 多名科研人员，建 multinational Novartis currently has about 500 RD scientists in the Zhangjiang Hi-Tech Park 立了完整的创新药物研发平台。诺华投资 10 亿美元在上海建设全新的研发园区，实 corporations in China in Shanghai’s Pudong New Area and has built multiple platforms for innovative 践对中国及中国病患的长期承诺。新园区毗邻上海科技大学，即将完成的一期建设项 drug discovery. As a long-term commitment to China and the Chinese patients, 目有七幢建筑，其中包括两幢世界一流的实验大楼。 Novartis is investing USD 1 billion to build an RD campus in Shanghai, located next to Shanghai Tech University. It is approaching the compl